Journal of Substance Use and Addiction Treatment Pshychiatric Mental Health
Adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine during the first 18 months postlaunch
The publisher did not provide an abstract — full text is available via the link below.